tradingkey.logo

tradingkey.logo
怜玢


Sanara Medtech Inc

SMTI
りォッチリストに远加
32.350USD
-0.190-0.58%
終倀 11-13 16:00ET
297.30M時䟡総額
損倱額盎近12ヶ月PER

Sanara Medtech Incに぀いお 䌁業名

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

Sanara Medtech Inc プロフィヌル


䌁業コヌドSMTI
䌚瀟名Sanara Medtech Inc
䞊堎日Apr 07, 1994
最高経営責任者「CEO」Muppalla (Suresh V)
埓業員数141
蚌刞皮類Ordinary Share
決算期末Apr 07
本瀟所圚地1200 Summit Avenue
郜垂FORT WORTH
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号76102
電話番号18175292300
りェブサむトhttps://sanaramedtech.com/
䌁業コヌドSMTI
䞊堎日Apr 07, 1994
最高経営責任者「CEO」Muppalla (Suresh V)

Sanara Medtech Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%
Ms. Ann Beal Salamone
Ms. Ann Beal Salamone
Director
Director
26.86K
+15.47%
Ms. Ann Beal Salamone
Ms. Ann Beal Salamone
Director
Director
26.86K
+15.47%
Ms. Ann Beal Salamone
Ms. Ann Beal Salamone
Director
Director
26.86K
+15.47%
Ms. Sara N. Ortwein
Ms. Sara N. Ortwein
Independent Director
Independent Director
25.41K
+18.16%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Seth D. Yon
Mr. Seth D. Yon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.89K
-3.46%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%
Mr. Ronald T. (Ron) Nixon
Mr. Ronald T. (Ron) Nixon
Executive Chairman of the Board
Executive Chairman of the Board
68.20K
+6.09%

よくある質問

Sanara Medtech Incの䞊䜍5名の株䞻は誰ですか


Sanara Medtech Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Seth D. Yon

Sanara Medtech IncSMTIの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Sanara Medtech Incの株匏を保有しおいる機関は131瀟あり、保有株匏の総垂堎䟡倀は玄1.42Mで、党䜓の15.50%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-599767.00増加しおいたす。

Sanara Medtech Incの最倧の収益源は䜕ですか


2026Q1においお、Soft tissue repair products郚門がSanara Medtech Incにずっお最倧の収益を生み出しおおり、その金額は25.24Mで、党収益の89.71%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。